Spain’s credit rating upgraded to ’A+’ by S&P on strong growth
Investing.com - Needham maintained its Buy rating and $3.00 price target on Lucid Diagnostics Inc (NASDAQ:LUCD), which has seen its shares surge 77.45% over the past year, following a positive Contractor Advisory Committee (CAC) meeting by MolDX. According to InvestingPro data, analyst price targets for LUCD range from $2.50 to $7.75, suggesting significant potential upside from current levels.
During the meeting, CAC panelists highlighted EsoGuard’s effectiveness as a rule-out test for Barrett’s esophagus (BE), noting its 99% negative predictive value (NPV) gives them confidence in patient triage capabilities.
The panel emphasized that EsoGuard’s non-invasive nature could significantly increase upper endoscopy compliance from the current approximately 10% rate in high-risk populations.
Panelists characterized the test as a "no-brainer" and "game-changer" in BE and esophageal cancer detection, while stressing that insurance coverage for tests like EsoGuard needs expansion due to high unmet need and low risk.
Based on the meeting’s tone and panel responses, Needham believes MolDX will likely begin covering EsoGuard, with a decision expected by early 2026 - a development the firm views as a major potential catalyst for Lucid Diagnostics shares. For deeper insights into LUCD’s financial health, growth prospects, and 10+ additional ProTips, visit InvestingPro.
In other recent news, Lucid Diagnostics reported its second-quarter 2025 financial results, showing a revenue of $1.2 million, which marks a 19% increase compared to the previous year. This revenue figure surpassed the FactSet consensus estimate of $1.1 million but did not meet Cantor Fitzgerald’s projection of $1.5 million. The company’s earnings per share (EPS) came in at -$0.10, slightly better than the anticipated -$0.11. BTIG has raised its price target for Lucid Diagnostics to $2.50, maintaining a Buy rating after a positive meeting with the Centers for Medicare & Medicaid Services (CMS) regarding Medicare coverage for the EsoGuard test. The CMS meeting saw unanimous positive feedback from clinicians about the EsoGuard test, which is a non-invasive screening tool for esophageal adenocarcinoma. Meanwhile, BTIG continues to hold a Buy rating with a $2.00 price target following Lucid’s Q2 results. Cantor Fitzgerald also reiterated its Overweight rating with a $3.00 price target, reflecting confidence in the company’s growth trajectory. These developments highlight ongoing interest and analysis from investment firms regarding Lucid Diagnostics’ financial performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.